معرفی
Bradley Broughton is an Associate Professor in the Department of Pharmacology at Monash University, affiliated with the Monash Biomedicine Discovery Institute and Victorian Heart Institute (VHI). As a Foundation for High Blood Pressure Research Fellow, he leads significant research initiatives in cardiovascular neuroscience with particular focus on stroke mechanisms and therapies. His work spans both basic science and translational applications.
Dr. Broughton's research interests center on understanding mechanisms contributing to brain damage after stroke, developing novel stroke therapies, and identifying imaging agents for detecting post-stroke cell loss. His expertise encompasses reactive oxygen species, calcium signaling, apoptosis, estrogen effects, Rho kinase, and nitric oxide pathways across systemic, pulmonary, and cerebral circulations. His work has identified gender differences in stroke outcomes and abnormalities in conditions including stroke, pulmonary hypertension, and atherosclerosis.
Analysis of his recent publications (2023-2024) reveals a strong focus on innovative stroke treatments, including peptide-based neuroprotective drugs (Hi1a), platelet-targeted thrombolysis, stem cell therapies, and relaxin administration. His work spans multiple disciplines including pharmacology, neuroscience, nanotechnology, and cardiovascular medicine, with particular emphasis on translating laboratory findings into potential clinical applications.
His scientific recognition includes:
- Foundation for High Blood Pressure Research Fellowship
- NHMRC Project Grant as Chief Investigator
- Grant-in-aid from the National Heart Foundation
- Membership on editorial boards for ISRN Stroke and Physiology Journal
Dr. Broughton serves as Primary Chief Investigator or Chief Investigator on multiple significant research projects, including 'Delivering a novel cell free therapy to improve stroke outcomes' (National Heart Foundation, 2021-2022), 'Development of a first-in-class neuroprotective drug for protecting the brain after stroke' (2019-2021), and 'Using amnion epithelial stem cells to treat stroke' (CASS Foundation, 2014). His collaborative approach is evident through partnerships with researchers across various disciplines and institutions.
As a senior member of the Vascular Biology and Immunopharmacology Group, Dr. Broughton contributes to Monash University's research ecosystem focused on cardiovascular and cerebrovascular diseases. His work aligns with UN Sustainable Development Goals related to good health and well-being, particularly through his contributions to stroke research and cardiovascular health.
